Upadacitinib

Status:
Red
Decision Date:
March 2020
 

Comments

RED1,2,3: NICE TA665 - treatment of  severe active rheumatoid arthritis. (Decision date - January 2021)


Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire CCG

Derby and Derbyshire CCG